

Freedom of Information Request: Our Reference CTMUHB_187_22

You asked:

I have a freedom of information request regarding the use of Biologic medicines. Could you please answer the following two questions:

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Apremilast
- Bimekizumab
- Brodalumab
- Certolizumab
- Dimethyl fumarate
- Etanercept - Enbrel
- Etanercept Biosimilar
- Guselkumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ixekizumab
- Risankizumab
- Secukinumab
- Tildrakizumab
- Ustekinumab

Q2. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Filgotinib
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Ozanimod
- Tofacitinib
- Ustekinumab
- Vedolizumab

Our response:

Please see provided in the tables below the data that Medicines Management are able to provide in relation to your request. The period relates to the months of February, March and April 2022.

Please note the majority of patients requiring biological treatment for dermatology conditions will be referred into the services of a neighbouring Health Boards; for Merthyr & Cynon and Rhondda, Taff Ely Localities patients are referred to Cardiff & Vale University Health Board and for the Bridgend Locality patient treatments are serviced by Swansea Bay University Health Board. We hope this

provides an explanation as to why our patient numbers are low for these medicines.

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Q1. Dermatology

Medicine	No of Patients
Adalimumab - Humira	**
Adalimumab Biosimilar	**
Apremilast	44
Bimekizumab	0
Brodalumab	0
Certolizumab	0
Dimethyl fumarate	**
Etanercept - Enbrel	0
Etanercept Biosimilar	0
Guselkumab	0
Infliximab - Remicade	0
Infliximab Biosimilar	**
Ixekizumab	0
Risankizumab	0

Q2. Gastroenterology

Medicine	No of Patients
Adalimumab - Humira	7
Adalimumab Biosimilar	116
Filgotinib	**
Golimumab	**
Infliximab - Remicade	**
Infliximab Biosimilar	184
Ozanimod	0
Tofacitinib	5
Ustekinumab	64
Vedolizumab	96